| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b84d70b7cd4d61189d8c85530f32a500 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate |
1995-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bdba53bc489292a66877007c5d65657 |
| publicationDate |
1997-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
SK-25296-A3 |
| titleOfInvention |
Protocadherin proteins and their uses |
| abstract |
Disclosed is a purified and isolated polynucleotide sequences encoding human protocadherins pc3 by amino acid sequence of SEQ ID NO: 110 or its polypeptide analog wherein one or more of the specified amino acids is deleted or replaced or wherein one or more non-naturally encoded amino acids are added without loss, and preferably with enhancement, of one or more of the biological activities or immunological characteristics specific for a protocadherin pc3, or with specific disablement of a particular ligand/antiligand binding function; the protocadherin; biologically active DNA vectors comprising the defined DNA sequence; vector; host cell transformed or transfected with the said DNA sequence allowing the expression of protocadherin polypeptides in the cells ; method for producing said peptide; antibody substances specific for the human protocadherin pc3, especially monoclonal antibody; hybridoma cell line producing monoclonal antibodies; and a method for modulating binding activity of said human protocadherin pc3. |
| priorityDate |
1994-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |